{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.60","value":"58.4"},{"groupId":"OG001","spread":"22.12","value":"56.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Global Health Index: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.6","value":"-6.0"},{"groupId":"OG001","spread":"23.85","value":"-6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"Global Health Index: End of Treatment"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Global Health Index: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.74","value":"70.0"},{"groupId":"OG001","spread":"23.54","value":"67.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Physical Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.61","value":"-4.7"},{"groupId":"OG001","spread":"23.36","value":"-6.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Physical Functioning: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Physical Functioning: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.75","value":"68.4"},{"groupId":"OG001","spread":"30.24","value":"64.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Role Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.27","value":"-8.6"},{"groupId":"OG001","spread":"32.90","value":"-8.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Role Functioning: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Role Functioning: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.47","value":"75.1"},{"groupId":"OG001","spread":"22.22","value":"75.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Emotional Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.09","value":"-2.1"},{"groupId":"OG001","spread":"23.16","value":"-6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"title":"Emotional Functioning: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"-25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Emotional Functioning: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.42","value":"81.9"},{"groupId":"OG001","spread":"19.79","value":"81.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Cognitive Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.61","value":"-7.6"},{"groupId":"OG001","spread":"22.24","value":"-5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"title":"Cognitive Functioning: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"-50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cognitive Functioning: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.07","value":"77.9"},{"groupId":"OG001","spread":"26.47","value":"75.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Social Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.44","value":"-6.9"},{"groupId":"OG001","spread":"29.37","value":"-7.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"title":"Social Functioning: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Social Functioning: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.98","value":"38.4"},{"groupId":"OG001","spread":"25.14","value":"39.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Fatigue: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.38","value":"6.0"},{"groupId":"OG001","spread":"26.61","value":"6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Fatigue: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Fatigue: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.30","value":"38.0"},{"groupId":"OG001","spread":"30.99","value":"38.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Pain: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.65","value":"2.7"},{"groupId":"OG001","spread":"30.07","value":"3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Pain: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Pain: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.89","value":"5.0"},{"groupId":"OG001","spread":"13.31","value":"6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Nausea and Vomiting: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.85","value":"3.4"},{"groupId":"OG001","spread":"19.22","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Nausea and Vomiting: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Nausea and Vomiting: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.74","value":"21.2"},{"groupId":"OG001","spread":"26.68","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Dyspnea: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.04","value":"5.7"},{"groupId":"OG001","spread":"27.33","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Dyspnea: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Dyspnea: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.04","value":"27.4"},{"groupId":"OG001","spread":"31.59","value":"30.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Insomnia: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.41","value":"0.9"},{"groupId":"OG001","spread":"33.26","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"title":"Insomnia: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Insomnia: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.70","value":"16.9"},{"groupId":"OG001","spread":"25.21","value":"15.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Appetite Loss: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.49","value":"4.7"},{"groupId":"OG001","spread":"28.47","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"title":"Appetite Loss: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Appetite Loss: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.58","value":"12.2"},{"groupId":"OG001","spread":"24.30","value":"13.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Constipation: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.57","value":"-1.3"},{"groupId":"OG001","spread":"27.05","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"259"}],"units":"Participants"}],"title":"Constipation: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Constipation: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.38","value":"6.3"},{"groupId":"OG001","spread":"18.49","value":"8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Diarrhea: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.08","value":"17.2"},{"groupId":"OG001","spread":"31.53","value":"10.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"title":"Diarrhea: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Diarrhea: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.15","value":"16.7"},{"groupId":"OG001","spread":"28.30","value":"18.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Financial Difficulties: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.69","value":"0.5"},{"groupId":"OG001","spread":"26.54","value":"1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"title":"Financial Difficulties: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"-33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Financial Difficulties: Last Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"description":"The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer participants. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).The EORTC-QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement. Scores are linearly transformed to a 0-100 scale. High scores for the global and functional domains indicate higher quality of life or functioning. Higher scores on the symptom scales represent higher levels of symptomatology or problems.","dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to EOT (up to approximately 42.9 months).","id":"OG000","title":"Ixazomib+ Lenalidomide + Dexamethasone"},{"description":"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first (up to approximately 41 months).","id":"OG001","title":"Placebo + Lenalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"ITT population included all randomized participants. Overall number analyzed is the number of participants available for analysis. Number analyzed is the number of participants available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, EOT and follow-up (up to approximately 97 months)","title":"Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) Questionnaire (EORTC-QLQ-C30)","type":"SECONDARY","unitOfMeasure":"score on a scale"}